摘要目的:探讨claudin-11（CLDN11）在各种肿瘤中的表达水平及其与临床预后的相关性。方法:采用ONCOMINE和UALCAN数据库分析CLDN11在肿瘤中的转录水平；利用KM-plotter数据库评估CLDN11对肿瘤的临床预后价值。结果:综合ONCOMINE和UALCAN数据库分析表明：CLDN11在大多数肿瘤中是低表达的，尤其在乳腺癌、结直肠腺癌、肾癌、肺腺癌等肿瘤中。使用KM-plotter数据库进行临床预后分析表明：CLDN11在食管癌、头颈部鳞状细胞癌、肾乳头状细胞癌、胰腺癌、胃癌、子宫内膜癌、睾丸生殖细胞肿瘤的高表达水平，预示更差的无进展生存期；而在肝癌、肉瘤中则预示更好的无进展生存期。CLDN11在肾透明细胞癌、肾乳头状细胞癌、胃癌、甲状腺癌和子宫内膜癌中的高表达水平预示更差的总生存期，而在乳腺癌中则预示更好的总生存期。结论:CLDN11能够作为多种肿瘤的预后指标，但是仍需要进一步的实验验证。

abstractsObjective:To investigate the expression level and prognostic value of claudin-11 (CLDN11) in various tumors.Methods:The mRNA levels of CLDN11 in tumors were firstly analyzed by ONCOMINE and UALCAN databases. Then, KM-plotter database was used to analyze the clinical prognostic value of CLDN11 in tumors.Results:ONCOMINE and UALCAN databases showed that CLDN11 expression was down-regulated in most of the cancers, especially in breast cancer, colorectal adenocarcinoma, kidney cancer, and lung adenocarcinoma. Clinical prognostic analysis from the KM-plotter database showed that high expression of CLDN11 predicted worse progression-free survival in esophageal cancer, head and neck squamous cell carcinoma, renal papillary cell carcinoma, pancreatic cancer, gastric cancer, endometrial cancer, and testicular germ cell tumor, but better progression-free survival in liver cancer and sarcoma. High expression of CLDN11 predicted worse overall survival in clear cell carcinoma of the kidney, renal papillary cell carcinoma, gastric cancer, thyroid cancer, and endometrial cancer, but better overall survival in breast cancer.Conclusion:CLDN11 can be used as a prognostic marker in most of the cancers. But more experimental studies are needed to confirm.